Alphamab Oncology ( ($HK:9966) ) has issued an update. Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio ...

BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

The HER2-targeted ADC showed clear benefits over Roche's Kadcyla in the adjuvant setting, and promising activity versus standard neoadjuvant therapy.

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. Sacituzumab tirumotecan significantly ...

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.

Abemaciclib plus endocrine therapy significantly improved overall survival, IDFS, and DRFS in HR-positive, HER2-negative, node-positive early breast cancer. Adjuvant abemaciclib (Verzenio; Eli Lilly) ...

Listening to stories of other breast cancer survivors gave Vanessa Pontes hope for her own treatment and future ...

Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.